Inefficient TLR4/MD-2 Heterotetramerization by Monophosphoryl Lipid A

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Casella, Carolyn R ^a   Mitchell, Thomas C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; DIPHOSPHORYL LIPID A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 2; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 2; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHORYL LIPID A; SHORT HAIRPIN RNA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DENDRITIC CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HETEROTETRAMERIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN POLYMERIZATION;

ANIMALS; HEK293 CELLS; HUMANS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LIPID A; LYMPHOCYTE ANTIGEN 96; MICE; MICE, INBRED C57BL; MUTANT PROTEINS; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; PHOSPHATES; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6; TOLL-LIKE RECEPTOR 4;

EID: 84876826729     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062622     Document Type: Article

References (56)

1. Garcon N, Chomez P, Van MM, (2007) GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives 1. Expert Rev Vaccines 6: 723-739.
2. Casella CR, Mitchell TC, (2008) Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 65: 3231-3240 10.1007/s00018-008-8228-6 [doi].
3. Ribi E, Parker R, Strain SM, Mizuno Y, Nowotny A, et al. (1979) Peptides as requirement for immuno therapy of the guinea-pig line-10 tumor with endotoxins. Cancer Immunol Immunother 7: 43-58.
4. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, et al. (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316: 1628-1632 316/5831/1628 [pii]; 10.1126/science.1138963 [doi].
5. Thompson BS, Chilton PM, Ward JR, Evans JT, Mitchell TC, (2005) The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J Leukoc Biol 78: 1273-1280 jlb.0305172 [pii]; 10.1189/jlb.0305172 [doi].
6. Bowen WS, Minns LA, Johnson DA, Mitchell TC, Hutton MM, et al. (2012) Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist. Sci Signal 5: ra13 5/211/ra13 [pii]; 10.1126/scisignal.2001963 [doi].
7. Embry CA, Franchi L, Nunez G, Mitchell TC, (2011) Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A. Sci Signal. 4: ra28 4/171/ra28 [pii]; 10.1126/scisignal.2001486 [doi].
8. Cekic C, Casella CR, Eaves CA, Matsuzawa A, Ichijo H, et al. (2009) Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J Biol Chem. 284: 31982-31991 M109.046383 [pii]; 10.1074/jbc.M109.046383 [doi].
9. Baldridge JR, McGowan P, Evans JT, Cluff C, Mossman S, et al. (2004) Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 4: 1129-1138.
10. Ismaili J, Rennesson J, Aksoy E, Vekemans J, Vincart B, et al. (2002) Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 168: 926-932.
11. Salkowski CA, Detore GR, Vogel SN, (1997) Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun 65: 3239-3247.
12. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ, (2000) Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 165: 618-622.
13. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, et al. (1999) Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11: 443-451.
14. Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS, (2000) Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol 165: 5780-5787.
15. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, et al. (1999) Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 189: 615-625.
16. Kim HM, Park BS, Kim JI, Kim SE, Lee J, et al. (2007) Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130: 906-917 S0092-8674(07)01021-5 [pii]; 10.1016/j.cell.2007.08.002 [doi].
17. Park BS, Song DH, Kim HM, Choi BS, Lee H, et al. (2009) The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458: 1191-1195 nature07830 [pii]; 10.1038/nature07830 [doi].
18. Prohinar P, Re F, Widstrom R, Zhang D, Teghanemt A, et al. (2007) Specific high affinity interactions of monomeric endotoxin.protein complexes with Toll-like receptor 4 ectodomain. J Biol Chem 282: 1010-1017 M609400200 [pii]; 10.1074/jbc.M609400200 [doi].
19. Yu L, Phillips RL, Zhang D, Teghanemt A, Weiss JP, et al. (2012) NMR studies of hexaacylated endotoxin bound to wild-type and F126A mutant MD-2 and MD-2.TLR4 ectodomain complexes. J Biol Chem 287: 16346-16355 M112.343467 [pii]; 10.1074/jbc.M112.343467 [doi].
20. Kobayashi M, Saitoh S, Tanimura N, Takahashi K, Kawasaki K, et al. (2006) Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. J Immunol 176: 6211-6218. 176/10/6211 [pii].
21. Teghanemt A, Re F, Prohinar P, Widstrom R, Gioannini TL, et al. (2008) Novel roles in human MD-2 of phenylalanines 121 and 126 and tyrosine 131 in activation of Toll-like receptor 4 by endotoxin. J Biol Chem 283: 1257-1266 M705994200 [pii]; 10.1074/jbc.M705994200 [doi].
22. Kawai T, Akira S, (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34: 637-650 S1074-7613(11)00190-7 [pii]; 10.1016/j.immuni.2011.05.006 [doi].
23. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, et al. (1998) MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 2: 253-258.
24. Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, et al. (2003) TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 4: 1144-1150.
25. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, et al. (2003) Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424: 743-748.
26. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, et al. (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301: 640-643.
27. Horng T, Barton GM, Flavell RA, Medzhitov R, (2002) The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 420: 329-333.
28. Kagan JC, Medzhitov R, (2006) Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 125: 943-955.
29. Lin SC, Lo YC, Wu H, (2010) Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 465: 885-890 nature09121 [pii]; 10.1038/nature09121 [doi].
30. Motshwene PG, Moncrieffe MC, Grossmann JG, Kao C, Ayaluru M, et al. (2009) An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4. J Biol Chem 284: 25404-25411 M109.022392 [pii]; 10.1074/jbc.M109.022392 [doi].
31. Flannery S, Bowie AG, (2010) The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochem Pharmacol 80: 1981-1991 S0006-2952(10)00454-5 [pii];10.1016/j.bcp.2010.06.020 [doi].
32. Gohda J, Matsumura T, Inoue J (2004) Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signaling. J Immunol 173: 2913-2917. 173/5/2913 [pii].
33. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, et al. (1999) TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13: 1015-1024.
34. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, et al. (2001) TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412: 346-351 10.1038/35085597 [doi];35085597 [pii].
35. Bjorkbacka H, Fitzgerald KA, Huet F, Li X, Gregory JA, et al. (2004) The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol Genomics 19: 319-330.
36. Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, et al. (2001) Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 167: 5887-5894.
37. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S, (1999) Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115-122.
38. Zanoni I, Ostuni R, Marek LR, Barresi S, Barbalat R, et al. (2011) CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. Cell 147: 868-880 S0092-8674(11)01221-9 [pii];10.1016/j.cell.2011.09.051 [doi].
39. Tanimura N, Saitoh S, Matsumoto F, Akashi-Takamura S, Miyake K, (2008) Roles for LPS-dependent interaction and relocation of TLR4 and TRAM in TRIF-signaling. Biochem Biophys Res Commun 368: 94-99 S0006-291X(08)00079-X [pii];10.1016/j.bbrc.2008.01.061 [doi].
40. Cusson-Hermance N, Khurana S, Lee TH, Fitzgerald KA, Kelliher MA, (2005) Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation. J Biol Chem 280: 36560-36566.
41. Sato S, Sugiyama M, Yamamoto M, Watanabe Y, Kawai T, et al. (2003) Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J Immunol 171: 4304-4310.
42. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, et al. (2003) IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 4: 491-496.
43. Hacker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, et al. (2006) Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439: 204-207.
44. Cekic C, Casella CR, Sag D, Antignano F, Kolb J, et al. (2011) MyD88-dependent SHIP1 regulates proinflammatory signaling pathways in dendritic cells after monophosphoryl lipid A stimulation of TLR4. J Immunol 186: 3858-3865 jimmunol.1001034 [pii];10.4049/jimmunol.1001034 [doi].
45. Tsukamoto H, Fukudome K, Takao S, Tsuneyoshi N, Kimoto M, (2010) Lipopolysaccharide-binding protein-mediated Toll-like receptor 4 dimerization enables rapid signal transduction against lipopolysaccharide stimulation on membrane-associated CD14-expressing cells. Int Immunol 22: 271-280 dxq005 [pii];10.1093/intimm/dxq005 [doi].
46. Akashi S, Saitoh S, Wakabayashi Y, Kikuchi T, Takamura N, et al. (2003) Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J Exp Med 198: 1035-1042 10.1084/jem.20031076 [doi];jem.20031076 [pii].
47. Akashi S, Shimazu R, Ogata H, Nagai Y, Takeda K, et al. (2000) Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol 164: 3471-3475. ji_v164n7p3471 [pii].
48. Saitoh S, Akashi S, Yamada T, Tanimura N, Kobayashi M, et al. (2004) Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int Immunol 16: 961-969 10.1093/intimm/dxh097 [doi];dxh097 [pii].
49. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, et al. (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223: 77-92.
50. Hagen SR, Thompson JD, Snyder DS, Myers KR, (1997) Analysis of a monophosphoryl lipid A immunostimulant preparation from Salmonella minnesota R595 by high-performance liquid chromatography. J Chromatogr A 767: 53-61.
51. Meng J, Gong M, Bjorkbacka H, Golenbock DT, (2011) Genome-wide expression profiling and mutagenesis studies reveal that lipopolysaccharide responsiveness appears to be absolutely dependent on TLR4 and MD-2 expression and is dependent upon intermolecular ionic interactions. J Immunol 187: 3683-3693 jimmunol.1101397 [pii];10.4049/jimmunol.1101397 [doi].
52. Gangloff M, (2012) Different dimerisation mode for TLR4 upon endosomal acidification? Trends Biochem Sci 37: 92-98 S0968-0004(11)00186-1 [pii];10.1016/j.tibs.2011.11.003 [doi].
53. Thoelen S, Van DP, Mathei C, Leroux-Roels G, Desombere I, et al. (1998) Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16: 708-714.
54. Thoelen S, De CN, Tornieporth N, (2001) A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine 19: 2400-2403.
55. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, et al. (2009) Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 5: 705-719. 9518 [pii].
56. Yamakawa N, Ohto U, Akashi-Takamura S, Takahashi K, Saitoh SI, et al. (2012) Human TLR4 polymorphism D299G/T399I alters TLR4/MD-2 conformation and response to a weak ligand monophosphoryl lipid A. Int Immunol. dxs084 [pii];10.1093/intimm/dxs084 [doi].